Perfuze Secures the US FDA’s 510(k) Clearance for its Zipline Access Catheters

Shots:The US FDA has granted 510(k) clearance to Zipline Access Catheters to treat acute ischemic strokes Zipline improves delivery of a large (070) & superbore (088) aspiration catheter to enhance trackability & simplify neuro-interventional procedures for faster as well as more efficient stroke treatment. Zipline also optimizes clot removal & improves success rates…

ByRidhi RastogiMarch 17, 2025

INSIGHTS+

Know Your Investor (March Edition): Qiming Venture Partners

Shots:In this reprise, we feature Qiming Venture Partners again, based on the investments in 2023. With more than 600 investments to date, Qiming boasts a strong portfolio of companies involved in Technology & Consumer and HealthcareIn 2023, Qiming closed 38 funding rounds comprising 11 in the first quarter, 10 in the second, 11…

BySenior EditorMarch 26, 2024

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in February 2024

Shots:The EMA approved 5 BLA and 8 New Chemical Entities in February 2024, leading to treatments for patients and advances in the healthcare industryIn February 2024, the major highlighted drugs were Reblozyl to treat Transfusion-Dependent Anemia and Velsipity for the treatment of Severely Active Ulcerative ColitisPharmaShots has compiled a list of a total…

BySenior EditorMarch 20, 2024

INSIGHTS+

Know Your Investor (January Edition): RA Capital Management LLC  

Shots:  New Year, New Us! Our hand-curated “Know Your Investor” reports will now be exploring leading investors of 2023  Founded in 2002, RA Capital forged ahead to become a key investor in life science and healthcare companies. In 2023, RA Capital closed 40 major investments in biopharma companies, devices, manufacturing, service offering firms, and diagnostics  …

BySenior EditorJanuary 31, 2024

VIEWPOINTS

Funds Raised: David Domzalski Discusses the Closing of VYNE Therapeutics’ Private Placement

Shots: David Domzalski, President & Chief Executive Officer at VYNE Therapeutics, in an invigorating conversation with PharmaShots The PIPE transaction generated $88M ensuring a steady cash flow through the end of 2025 and multiple anticipated clinical catalysts across VYNE’s BET inhibitor platform David believes the financing will be instrumental in the advancement of VYN201, into…

BySaurabh ChaubeyJanuary 29, 2024

VIEWPOINTS

PharmaShots Interview: Indapta’s Mark Frohlich Shares Insights on the $50M Series A Financing

In an interview with PharmaShots, Mark Frohlich, CEO at Indapta Therapeutics shared his views on the closing of $50M A financing and how it will advance its cell therapy drug developmentShots:The company closes $50M A financing, co-led by RA Capital Management, LP, Vertex Ventures HC, and Bayer AG with Mark Frohlich appointed as M.D.,…

BySenior EditorMay 23, 2022

Perfuze Secures the US FDA’s 510(k) Clearance for its Zipline Access Catheters

Know Your Investor (March Edition): Qiming Venture Partners

Insights+: EMA Marketing Authorization of New Drugs in February 2024

Know Your Investor (January Edition): RA Capital Management LLC

Funds Raised: David Domzalski Discusses the Closing of VYNE Therapeutics’ Private Placement

PharmaShots Interview: Indapta’s Mark Frohlich Shares Insights on the $50M Series A Financing

Contact US

OUR INFORMATION

FOLLW US

Perfuze Secures the US FDA’s 510(k) Clearance for its Zipline Access Catheters

Know Your Investor (March Edition): Qiming Venture Partners

Insights+: EMA Marketing Authorization of New Drugs in February 2024

Know Your Investor (January Edition): RA Capital Management LLC

Funds Raised: David Domzalski Discusses the Closing of VYNE Therapeutics’ Private Placement

PharmaShots Interview: Indapta’s Mark Frohlich Shares Insights on the $50M Series A Financing

FOLLW US

Sign Up to Our Newsletter

Know Your Investor (January Edition): RA Capital Management LLC  